Drug
Duvelisib clinical trials
Also written IPI-145, Copiktra and INK-1197.
- studies test it
- 50
- open now
- 9
- in phase 3
- 5
- first study started
- 2011
Keep track of what changes. Save the duvelisib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
49 studies that test it; most in 2013 (8); 1 more planned to start later
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 8 |
| 2014 | 4 |
| 2015 | 4 |
| 2016 | 2 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 6 |
| 2021 | 6 |
| 2022 | 5 |
| 2023 | 1 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 25
- Phase 2
- 25
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 27 · Other 23
SecuraBio (23) · Washington University School of Medicine (3) · Dana-Farber Cancer Institute (2) · National Cancer Institute (NCI) (2) · City of Hope Medical Center (2) · Emory University (2) · AbbVie (2) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (2)
Often tested with
Tested in the same studies.
Nivolumab (3) · Venetoclax (3) · Cc-486 (3) · Fludarabine (1) · Cyclophosphamide (1) · Rituximab (1) · Docetaxel (1) · Midazolam (1)
Studies
Open first, then newest update. How each study uses duvelisib is read from its arms, and is right about nine times in ten.
Testing it · 50
- Duvelisib Maintenance for the Treatment of Peripheral T-Cell LymphomasRecruitingPhase 2City of Hope Medical CenterNCT07293403Written as Duvelisib
- Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT04803201Written as Duvelisib
- A Study of Ruxolitinib and Duvelisib in People With LymphomaRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT05010005Written as Duvelisib
- A Study of Topical Duvelisib in Participants With Early-stage Mycosis FungoidesNot yet recruitingPhase 1SecuraBioNCT07714187Written as Duvelisib
- Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)RecruitingPhase 1/2Jonsson Comprehensive Cancer CenterNCT06810778Written as Duvelisib
- A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)RecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07001384Written as Duvelisib
- Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)RecruitingPhase 2Liling ZhangNCT05976997Written as Duvelisib, Chidamide
- A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) PhenotypeRecruitingPhase 3SecuraBioNCT06522737Written as Duvelisib
- A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid TumorsNot yet recruitingPhase 1/2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05508659Written as Duvelisib
- A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLLActive, not recruitingPhase 1/2Dana-Farber Cancer InstituteNCT02158091Written as IPI-145
- Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCCCompletedPhase 2Kartik Sehgal, MDNCT05057247Written as Duvelisib
- Duvelisib Following Chimeric Antigen Receptor T-Cell TherapyActive, not recruitingPhase 1Washington University School of MedicineNCT05044039Written as Duvelisib
- Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary SyndromeActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04652960Written as Duvelisib
- Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell LymphomasTerminatedPhase 2Washington University School of MedicineNCT04331119Written as Duvelisib
- Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RSActive, not recruitingPhase 1/2Dana-Farber Cancer InstituteNCT03534323Written as Duvelisib
- Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingPhase 2City of Hope Medical CenterNCT03961672Written as Duvelisib
- Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable MelanomaTerminatedPhase 1/2John KirkwoodNCT04688658Written as Duvelisib
- Duvelisib in Combination With BMS-986345 in Lymphoid MalignancyCompletedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05065866Written as Duvelisib
- A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)CompletedPhase 2SecuraBioNCT03372057Written as Duvelisib
- Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS StudyCompletedEarly Phase 1Emory UniversityNCT04890236Written as Duvelisib
See all 50 studies that test duvelisib →
Given in every arm · 3 — duvelisib is usual care beside what is tested
- Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell LymphomasCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT02783625Written as duvelisib
- A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)TerminatedPhase 1/2SecuraBioNCT02391545Written as Duvelisib
- Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic MalignanciesCompletedPhase 1SCRI Development Innovations, LLCNCT01871675Written as IPI-145
Codes
What other systems call duvelisib · ClinicalTrials.gg INT006442
- MeSH (NLM) C586691duvelisibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 610V23S0JIDUVELISIBConfirmed FDA, NLM, Wikidata
- RxNorm 2058509One source FDA
- Wikidata Q27077129duvelisibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C99225DuvelisibOne source FDA
- DrugBank DB11952One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C586691 | duvelisib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 610V23S0JI | DUVELISIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2058509 | — | One source FDA |
| Wikidata | Q27077129 | duvelisib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C99225 | Duvelisib | One source FDA |
| DrugBank | DB11952 | — | One source Wikidata |
Also registered as duvelisib monohydrate (UNII 4WD61MR063).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.